查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010044

抗生素市場：2026-2032年全球市場預測（依產品類型、給藥途徑、類型、抗菌頻譜、應用及通路分類）

Antibiotics Market by Product Type, Route Of Administration, Type, Spectrum, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗生素市值將達到 489.4 億美元，到 2026 年將成長至 519.5 億美元，到 2032 年將達到 792.6 億美元，複合年成長率為 7.13%。

主要市場統計數據
基準年 2025 489.4億美元
預計年份：2026年 519.5億美元
預測年份 2032 792.6億美元
複合年成長率 (%) 7.13%

簡明扼要地介紹全球抗生素市場趨勢，闡明臨床需求、監管變化、抗生素抗藥性壓力以及供應鏈的複雜性。

全球抗生素市場正處於一個轉折點，臨床需求、監管變化和供應鏈重組在此交匯融合。人們對抗菌素抗藥性的認知不斷提高，加上抗菌藥物管理政策的不斷完善和對生產品質監管的日益嚴格，已顯著改變了醫院、門診診所和獸醫領域的需求模式。同時，技術驅動的分銷、門診治療的擴展以及給藥途徑偏好的改變，也正在影響籌資策略和處方集決策。

管理現代化、監管加強、診斷技術創新和供應鏈韌性如何重塑整個抗生素產業的研發、生產和商業模式。

近年來，變革性的變化重新分配了競爭優勢，改變了抗生素的研發、生產和分銷方式。其中一個主要促進因素是基於改進的診斷技術和監測手段而加強的抗菌藥物管理。這種對維持治療效用的重視改變了處方行為，並催生了對具有清晰抗菌頻譜和更佳安全性的藥物的需求。除了在臨床實踐中合理使用外，監管機構正在實施更嚴格的檢查和品質標準，促使生產商加強投入以加強合規性，並重新評估與契約製造（CMO）的關係。

對關稅波動對抗生素價值鏈供應鏈結構、採購韌性和製造策略的影響進行系統性評估。

關稅的徵收及相關貿易政策調整暴露了活性藥物成分和成品抗生素長期供應鏈中的許多脆弱性。面對關稅帶來的成本壓力，跨國製造商和經銷商正在重新評估籌資策略，許多企業正在探索利用區域生產基地和多元化的供應商組合來緩解單一來源供應鏈造成的衝擊。在某些情況下，製造商正在承擔額外成本以維持供貨管道和合約關係，而其他公司則在調整定價和分銷協議，以維持利潤率和供應的連續性。

為了明確每種產品在路線、來源、分銷管道、應用和抗菌頻譜的細微差別，從而有助於有針對性的開發、商業化和供應決策。

細分市場分析揭示了每種產品類別、給藥途徑、製劑來源、分銷管道、適應症和抗菌頻譜特徵的不同機會和營運重點。產品類型包括Aminoglycosides、BETA-內醯胺類（包括單環胺基類醯胺類和青黴素類等亞類）、大環內酯類、磺胺類藥物和四環黴素，每種藥物都有其獨特的抗藥性考慮、治療定位和生命週期策略。給藥途徑包括口服、注射和局部用藥，這些因素會影響臨床誘導模式、生產複雜性和分銷物流。

識別重點地區獨特的監管、採購和臨床部署模式，以指導差異化的市場進入和供應策略。

區域趨勢差異顯著，反映出法律規範、醫療服務模式和採購慣例的差異，這些差異帶來了獨特的策略挑戰。在美洲，醫院抗菌藥物管理計畫和整合醫療系統中的採購越來越受到重視，這些系統優先考慮品質、處方集相容性和療效評估。在這種環境下，能夠提供強而有力的臨床證據、可靠的低溫運輸和配送體系，並能快速回應醫院競標週期的供應商備受青睞。

製造商、經銷商和創新者如何協調生產品質、監管靈活性和臨床參與，以確保抗生素的可及性並促進永續的抗生素產品組合？

抗生素生態系統中的主要企業正在調整其優先事項，以平衡其管理責任、商業性永續性和業務永續營運。成熟的製藥公司正在投資升級生產設施、完善品質保證系統並建立策略夥伴關係，以確保傳統產品和差異化產品的供應更加可靠。非專利藥生產商則專注於成本效益高的製程和製劑創新，以支持門診治療模式，促進從注射劑到口服藥物的轉變，並提供緩釋製劑選擇。

採取切實可行的策略行動，增強製造韌性、管理協調、供應多元化和證據生成，以實現永續的商業性和臨床成功。

行業領導企業應優先考慮能夠降低業務風險並增強其臨床和商業性地位的綜合方法。首先，應投資於生產柔軟性和品質改進，以確保區域供應的連續性，並能快速回應需求波動，同時確保跨轄區監管合規。這種基礎性方法能夠降低政策變革帶來的衝擊，並維持醫療保健採購方的信任。

透過結合二手文獻、監管指南和專家一手檢驗，嚴格的證據整合可提供可操作的供應鏈、臨床和商業性見解。

本研究途徑結合了系統性的二手資料研究和有針對性的原始檢驗，以建立可靠的證據基礎。二級資訊來源包括同行評審的臨床文獻、監管指導文件、藥典標準以及公開的採購和競標信息，涵蓋了政策趨勢、臨床指南和品質預期。為了補充這些資料，研究人員還對臨床醫生、處方集管理人員、採購經理、生產品質專家和法規事務專業人員進行了訪談，以了解當前的營運實際情況和策略重點。

整合策略挑戰，以平衡抗菌生態系統中的管理、監管合規、供應彈性和商業性永續性。

這些分析表明，抗生素產業將繼續受到臨床管理、更嚴格的監管和供應鏈韌性三者交互作用的影響。積極將生產品質與管理原則結合、投資於基於診斷的診療路徑並實現相關人員多元化的利益相關者，將更有能力應對政策變化和日益複雜的採購流程。同時，優先考慮臨床價值、穩定供應和與醫療系統夥伴關係的商業化策略，將有助於實現永續的藥物取得和可靠性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗生素市場：依產品類型分類

  • Aminoglycosides
  • BETA-內醯胺
    • 單環胺基類抗生素
    • 青黴素
  • 大環內酯類
  • 磺胺類藥物
  • 四環黴素

第9章：抗生素市場：依給藥途徑分類

  • 口服
  • 腸外
  • 外用

第10章：抗生素市場：依類型分類

  • 自然的
  • 合成

第11章：抗生素市場：依作用頻譜

  • 頻譜
  • 窄頻譜

第12章 抗生素市場：依應用領域分類

  • 人類
  • 獸用

第13章：抗生素市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 抗生素市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：抗生素市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 抗生素市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國抗生素市場

第18章 中國抗生素市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc
  • Astellas Pharma Inc
  • Astra Zeneca plc
  • Aurobindo Pharma Ltd
  • Bayer AG
  • Bristol Myers Squibb Company
  • Cipla Ltd
  • Dr Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Glaxo Smith Kline plc
  • Johnson & Johnson Services Inc
  • Lupin Limited
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Zydus Lifesciences Ltd
Product Code: MRR-434CCDA0512F

The Antibiotics Market was valued at USD 48.94 billion in 2025 and is projected to grow to USD 51.95 billion in 2026, with a CAGR of 7.13%, reaching USD 79.26 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 48.94 billion
Estimated Year [2026] USD 51.95 billion
Forecast Year [2032] USD 79.26 billion
CAGR (%) 7.13%

A concise primer on global antibiotics dynamics clarifying drivers of clinical demand regulatory shifts resistance pressures and supply chain complexities

The global antibiotics landscape is at an inflection point defined by the convergence of clinical need, regulatory recalibration, and supply chain restructuring. Increasing awareness of antimicrobial resistance, coupled with evolving stewardship policies and heightened scrutiny of manufacturing quality, has reshaped demand patterns across hospitals, outpatient settings, and veterinary practice. At the same time, technology-enabled distribution, expanded outpatient therapeutics, and shifts in route-of-administration preference are influencing procurement strategies and formulary decisions.

Clinicians and procurement leaders now balance efficacy, resistance profiles, and access considerations while navigating a more complex supplier ecosystem. Pharmaceutical manufacturers face pressure to optimize production quality, comply with stricter regulatory expectations, and invest selectively in antibiotic R&D that leverages novel modalities or extends lifecycle value through differentiated formulations. The intersection of these forces requires stakeholders to adopt integrated approaches that address clinical, commercial, and operational dimensions concurrently.

This introduction frames the subsequent analysis by situating current dynamics within the broader context of patient safety, regulatory vigilance, and economic constraints, ensuring that readers can interpret subsequent sections through a lens of pragmatic risk management and opportunity identification.

How stewardship modernization regulatory tightening diagnostics innovation and supply chain resilience are reshaping development production and commercial models across the antibiotics landscape

Over recent years, transformative shifts have redistributed competitive advantage and altered how antibiotics are developed, produced, and distributed. A primary driver has been intensified antimicrobial stewardship informed by improved diagnostics and surveillance; this focus on preserving therapeutic utility has changed prescribing behavior and generated demand for agents with well-defined spectrums and strong safety profiles. Parallel to clinical stewardship, regulatory bodies have introduced more exacting inspections and quality expectations, prompting manufacturers to invest in compliance upgrades and to reconsider contract manufacturing relationships.

Technological advances in diagnostics are shortening the time to targeted therapy, which in turn elevates interest in narrow-spectrum agents when appropriate and accelerates adoption of parenteral-to-oral switch strategies that strengthen outpatient treatment pathways. Manufacturing resilience has become a strategic priority, with onshoring and regional diversification emerging as responses to geopolitical risk and supply disruptions. These shifts have also encouraged new commercial models, including value-based contracting and partnership structures between innovators and generic producers that extend product lifecycles while managing cost pressures.

Taken together, these trends signal a market environment that rewards operational excellence, agility in clinical engagement, and investment in differentiated formulations that align with contemporary stewardship and care-delivery paradigms.

Assessing the systemic implications of tariff shifts on supply chain configuration procurement resilience and manufacturing strategies within the antibiotics value chain

The imposition of tariffs and related trade policy adjustments has exposed vulnerabilities across long-established supply chains for active pharmaceutical ingredients and finished antibiotics. Tariff-driven cost pressures have prompted multinational manufacturers and distributors to reassess sourcing strategies, with many exploring regional production nodes and diversified supplier portfolios to mitigate exposure to single-source disruptions. In some cases, manufacturers have absorbed incremental costs to preserve access and contractual relationships, while others have restructured pricing and distribution agreements to maintain margins and continuity of supply.

The cumulative impact extends beyond unit costs to affect inventory strategies and lead times, compelling procurement teams to enlarge safety stocks or to seek alternative routes of administration that reduce dependence on constrained product lines. Contract manufacturers and API suppliers have experienced shifts in order patterns, as clients weigh the trade-offs between cost, quality, and geopolitical risk. Regulatory compliance considerations remain central, since any shift in production location or supplier requires careful validation to ensure product integrity and uninterrupted regulatory approvals.

Overall, tariff-related dynamics have accelerated strategic realignment across the value chain, reinforcing the importance of supply chain transparency, dual sourcing where feasible, and investment in manufacturing flexibility to sustain access and therapeutic continuity amid ongoing policy uncertainty.

Clarifying nuanced product route origin channel application and spectrum distinctions to inform targeted development commercialization and supply decisions

Segmentation analysis reveals differentiated opportunities and operational priorities across product classes, routes of administration, formulation origins, distribution channels, applications, and spectrum characteristics. Product type distinctions include Aminoglycosides, Beta Lactams with subcategories such as Monobactams and Penicillins, Macrolides, Sulfonamides, and Tetracyclines, each presenting unique resistance considerations, therapeutic niches, and lifecycle strategies. Route of administration considerations span oral, parenteral, and topical therapies, which influence clinical adoption patterns, manufacturing complexity, and channel logistics.

The dichotomy between natural and synthetic types highlights divergent R&D trajectories and regulatory expectations, where natural derivatives may demand distinct sourcing and quality controls while synthetic molecules can offer scalable manufacturing advantages. Distribution channels encompass hospital pharmacy, online pharmacy, and retail pharmacy, each with different procurement cycles, inventory management practices, and stakeholder touchpoints that affect market access strategies. Application segmentation across human and veterinary uses introduces different regulatory frameworks, dosing paradigms, and stewardship imperatives that shape product positioning.

Finally, spectrum classification into broad-spectrum and narrow-spectrum agents affects formulary placement, diagnostic dependency, and stewardship alignment. Integrating these segmentation lenses provides actionable clarity for product development prioritization, commercialization tactics, and supply chain design to meet the nuanced demands of diverse clinical and commercial settings.

Delineating distinct regional regulatory procurement and clinical adoption patterns across major territories to guide differentiated market entry and supply strategies

Regional dynamics are materially different and reflect variations in regulatory frameworks, healthcare delivery models, and procurement practices which create distinct strategic imperatives. In the Americas, there is heightened emphasis on hospital stewardship programs and integrated health-system procurement that prioritizes quality, formulary alignment, and outcome measurement. This environment rewards suppliers that can demonstrate robust clinical evidence, cold-chain and distribution reliability, and responsiveness to hospital tender cycles.

In Europe, Middle East & Africa, heterogeneity across national regulatory capacities and reimbursement structures creates diverse pathways to adoption. Some markets emphasize generics and cost containment while others prioritize access and quality assurance, encouraging suppliers to adopt flexible pricing models and to invest in local regulatory partnerships. The region also exhibits active antimicrobial surveillance initiatives that influence product selection and stewardship deployment.

Asia-Pacific encompasses mature markets with sophisticated hospital networks alongside emerging markets where access and affordability remain central. Rapid urbanization and expanding outpatient care are shifting consumption patterns toward oral and simplified parenteral therapies, while several countries are strengthening regulatory oversight and local manufacturing capabilities. Across all regions, tailored market entry strategies that reflect local clinical guidelines, procurement frameworks, and supply chain realities produce the best outcomes for sustained access and commercial viability.

How manufacturers distributors and innovators are aligning manufacturing quality regulatory agility and clinical engagement to protect access and drive sustainable antibiotic portfolios

Leading companies across the antibiotics ecosystem are recalibrating priorities to balance stewardship obligations with commercial sustainability and operational resilience. Established pharmaceutical manufacturers are investing in manufacturing upgrades, quality assurance systems, and strategic partnerships that enable more reliable supply of both legacy and differentiated products. Generic producers are focusing on cost-effective processes and formulation innovations that facilitate parenteral-to-oral switches and extended-release options to support outpatient care models.

Smaller innovators and specialty firms are pursuing niche differentiation through novel delivery formats, targeted-spectrum agents, and companion diagnostics that enhance clinical appropriateness and support premium positioning. Across the value chain, strategic alliances between innovators, contract manufacturers, and distribution partners are becoming more common as a way to share risk and accelerate access. Additionally, companies are increasingly transparent about stewardship commitments and clinical evidence generation, recognizing that payers and health systems now evaluate antibiotics within broader antimicrobial resistance strategies.

Corporate strategies that combine manufacturing excellence, regulatory agility, and credible clinical engagement tend to perform best in preserving market access and fostering long-term partnerships with healthcare providers and procurement organizations.

Practical strategic actions to enhance manufacturing resilience stewardship alignment supply diversification and evidence generation for sustained commercial and clinical success

Industry leaders should prioritize integrated actions that simultaneously reduce operational risk and strengthen clinical and commercial positioning. First, invest in manufacturing flexibility and quality upgrades to enable regional supply continuity and rapid response to demand shifts while ensuring regulatory compliance across jurisdictions. This foundational work reduces vulnerability to policy disruptions and protects reputation with healthcare purchasers.

Second, embed stewardship-aligned product strategies by developing and promoting diagnostics-linked prescribing pathways, and by tailoring formulations that enable safe outpatient management and reduced hospital stays. These efforts not only support public health objectives but also align product value with payer priorities. Third, diversify supplier networks and consider nearshoring where feasible to mitigate tariff and geopolitical exposures, while maintaining rigorous supplier qualification and validation processes to preserve product integrity.

Fourth, cultivate collaborative commercial models with health systems and payers that emphasize outcomes, supply reliability, and appropriate use. Finally, accelerate clinical evidence generation that demonstrates real-world impact on patient outcomes and resistance patterns, thereby strengthening formulary positioning and supporting long-term access agreements. Taken together, these steps create a defensible platform for both stewardship and business continuity.

A rigorous evidence synthesis combining secondary literature regulatory guidance and primary expert validation to deliver actionable supply chain clinical and commercial insights

The research approach combined systematic secondary research with targeted primary validation to construct a robust evidence base. Secondary sources included peer-reviewed clinical literature, regulatory guidance documents, pharmacopoeial standards, and publicly available procurement and tender information to map policy trajectories, clinical guidelines, and quality expectations. This foundation was complemented by primary interviews with clinicians, formulary managers, procurement leaders, manufacturing quality specialists, and regulatory affairs professionals to capture contemporary operational realities and strategic priorities.

Data triangulation methods were used to reconcile differences between published guidance and on-the-ground practice, with emphasis on supply chain case studies that illustrate how tariffs and regulatory shifts materially affect procurement and production decisions. Analytical frameworks focused on segmentation-driven insights, scenario analysis for supply disruption responses, and comparative regional assessments. Quality control measures included source verification, expert peer review of synthesized findings, and transparent documentation of assumptions and analytical steps to ensure reproducibility and practical relevance to decision-makers.

Synthesis of the strategic imperatives for balancing stewardship regulatory compliance supply resilience and commercial sustainability within the antibiotics ecosystem

The cumulative analysis underscores that the antibiotics sector will continue to be shaped by the interplay of clinical stewardship, regulatory rigor, and supply chain resilience. Stakeholders that proactively align manufacturing quality with stewardship principles, invest in diagnostic-enabled care pathways, and diversify sourcing will be better positioned to navigate policy shifts and procurement complexity. At the same time, commercialization strategies that emphasize clinical value, reliable supply, and partnerships with health systems will foster sustainable access and credibility.

Decisions taken now around production footprint, formulation development, and evidence generation will have long-term implications for access, cost management, and therapeutic effectiveness. Organizations that integrate clinical science, operations, and commercial strategy into a coherent roadmap will not only mitigate near-term risks but also create differentiated propositions that support appropriate antibiotic use and meet evolving healthcare priorities. The conclusion invites leaders to act deliberately and to leverage targeted intelligence when shaping investment, procurement, and clinical engagement choices.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antibiotics Market, by Product Type

  • 8.1. Aminoglycosides
  • 8.2. Beta Lactams
    • 8.2.1. Monobactams
    • 8.2.2. Penicillins
  • 8.3. Macrolides
  • 8.4. Sulfonamides
  • 8.5. Tetracyclines

9. Antibiotics Market, by Route Of Administration

  • 9.1. Oral
  • 9.2. Parenteral
  • 9.3. Topical

10. Antibiotics Market, by Type

  • 10.1. Natural
  • 10.2. Synthetic

11. Antibiotics Market, by Spectrum

  • 11.1. Broad Spectrum
  • 11.2. Narrow Spectrum

12. Antibiotics Market, by Application

  • 12.1. Human
  • 12.2. Veterinary

13. Antibiotics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Antibiotics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Antibiotics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Antibiotics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Antibiotics Market

18. China Antibiotics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. AbbVie Inc
  • 19.7. Astellas Pharma Inc
  • 19.8. Astra Zeneca plc
  • 19.9. Aurobindo Pharma Ltd
  • 19.10. Bayer AG
  • 19.11. Bristol Myers Squibb Company
  • 19.12. Cipla Ltd
  • 19.13. Dr Reddy's Laboratories Ltd
  • 19.14. Eli Lilly and Company
  • 19.15. Glaxo Smith Kline plc
  • 19.16. Johnson & Johnson Services Inc
  • 19.17. Lupin Limited
  • 19.18. Merck & Co Inc
  • 19.19. Novartis AG
  • 19.20. Pfizer Inc
  • 19.21. Sanofi S A
  • 19.22. Sun Pharmaceutical Industries Ltd
  • 19.23. Teva Pharmaceutical Industries Ltd
  • 19.24. Zydus Lifesciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBIOTICS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBIOTICS MARKET SIZE, BY MONOBACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBIOTICS MARKET SIZE, BY MONOBACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBIOTICS MARKET SIZE, BY MONOBACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBIOTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBIOTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBIOTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBIOTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBIOTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBIOTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBIOTICS MARKET SIZE, BY NATURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBIOTICS MARKET SIZE, BY NATURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBIOTICS MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBIOTICS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBIOTICS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBIOTICS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBIOTICS MARKET SIZE, BY BROAD SPECTRUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBIOTICS MARKET SIZE, BY BROAD SPECTRUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBIOTICS MARKET SIZE, BY BROAD SPECTRUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBIOTICS MARKET SIZE, BY NARROW SPECTRUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBIOTICS MARKET SIZE, BY NARROW SPECTRUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBIOTICS MARKET SIZE, BY NARROW SPECTRUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBIOTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBIOTICS MARKET SIZE, BY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBIOTICS MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBIOTICS MARKET SIZE, BY VETERINARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBIOTICS MARKET SIZE, BY VETERINARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBIOTICS MARKET SIZE, BY VETERINARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ANTIBIOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ANTIBIOTICS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)